Magnesium potentiates neuromuscular blockade with cisatracurium during cardiac surgery

Canadian Journal of Anesthesia

Volumn 50, Issue 2, 2003, Pages 172-178

  Pinard, Anne Marie ^a   Donati, François ^b   Martineau, Raymond ^b   Denault, André Y ^b   Taillefer, Jean ^b   Carrier, Michel ^b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISATRACURIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOPYRRONIUM BROMIDE; MAGNESIUM SULFATE; MIDAZOLAM; MIVACURIUM; MORPHINE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PROPOFOL; ROCURONIUM; SCOPOLAMINE; SUFENTANIL; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; VECURONIUM;

ADULT; AGED; ANESTHESIA INDUCTION; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; ELECTIVE SURGERY; ELECTROMYOGRAPHY; FEMALE; HAND MUSCLE; HEART ARRHYTHMIA; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; INTUBATION; MAINTENANCE DRUG DOSE; MALE; MUSCLE TWITCH; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TEMPERATURE; ULNAR NERVE;

EID: 0037301501     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03017852     Document Type: Article

References (28)

1. Peck CH, Meltzer SJ. Anesthesia in human beings by intravenous injection of magnesium sulfate. JAMA 1916; 67: 1131-3.
2. Delhumeau A, Granry JC, Monrigal JP, Costerousse F. Therapeutic use of magnesium in anaesthesia and intensive care (French). Ann Fr Anesth Reanim 1995; 14: 406-16.
3. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999; 83: 302-20.
4. Gomez MN. Magnesium and cardiovascular disease. Anesthesiology 1998; 89: 222-40.
5. Idama TO, Lindow SW. Magnesium sulphate: a review of clinical pharmacology applied to obstetrics. Br J Obstet Gynaecol 1998; 105: 260-8.
6. James MFM. Clinical use of magnesium infusions in anesthesia. Anesth Analg 1992; 74: 129-36.
7. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92: 883-9.
8. England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268: 2395-402.
9. Horner SM. Magnesium and arrhythmias in acute myocardial infarction. Coron Artery Dis 1996; 7: 359-63.
10. Giesecke AH Jr, Morris RE, Dalton MD, Stephen CR. Of magnesium, muscle relaxants, toxemic parturients, and cats. Anesth Analg 1968; 47: 689-95.
11. Ahn EK, Bai SJ, Cho BJ, Shin YS. The infusion rate of mivacurium and its spontaneous neuromuscular recovery in magnesium-treated parturients. Anesth Analg 1998; 86: 523-6.
12. Fuchs-Buder T, Wilder-Smith OHG, Borgeat A, Tassonyi E. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth 1995; 74: 405-9.
13. Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth 1996; 76: 565-6.
14. Fuchs-Buder T, Ziegenfub T, Lysakowski K, Tassonyi E. Antagonism of vecuronium-induced neuromuscular block in patients pretreated with magnesium sulphate: dose-effect relationship of neostigmine. Br J Anaesth 1999; 82: 61-5.
15. Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular blocking agents. Anesthesiology 1970; 32: 23-7.
16. James MFM, Schenk PA, Van Der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth 1991; 66: 247-9.
17. Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth 1997; 79: 122-4.
18. Stacey MRW, Barclay K, Asai T, Vaughan RS. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia 1995; 50: 933-6.
19. Searle NR, Thomson I, Dupont C, et al. A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1999; 13: 20-5.
20. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf 1996; 15: 261-73.
21. Buzello W, Pollmaecher T, Schluermann D, Urbanyi B. The influence of hypothermic cardiopulmonary bypass on neuromuscular transmission in the absence of muscle relaxants. Anesthesiology 1986; 64: 279-81.
22. Cammu G, Coddens J, Hendrickx J, Deloof T. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass. Br J Anaesth 2000; 84: 587-90.
23. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36: 27-40.
24. Del Castillo J, Engbaek L. The nature of the neuromuscular block produced by magnesium. J Physiol 1954; 124: 370-84.
25. Altura BM, Altura BT. Role of magnesium in pathophysiological processes and the clinical utility of magnesium ion selective electrodes. Scand J Clin Lab Invest 1996; 56(Suppl 224): 211-34.
26. Somjen GG, Baskerville EN. Effect of excess magnesium on vagal inhibition and acetylcholine sensitivity of the mammalian heart in situ and in vitro. Nature 1968; 217: 679-80.
27. Altura BM, Altura BT. Magnesium and vascular tone and reactivity. Blood Vessels 1978; 15: 5-16.
28. 2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 1987; 65: 729-45.